Zepbound for Diabetes: Off-Label Use, Evidence, Risks, and Clinical Tradeoffs

What Zepbound Actually Is (and What It Is Not)

Zepbound is the brand name Eli Lilly uses to market tirzepatide specifically for chronic weight management. The FDA approved it in November 2023 for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea [1]. It is not approved for type 2 diabetes.

The same tirzepatide molecule is marketed separately as Mounjaro, which received FDA approval in May 2022 for type 2 diabetes [2]. Both products contain identical tirzepatide. They use the same pen injector device. The difference is regulatory labeling and, by extension, how insurers process claims.

This dual-brand strategy is not unique. Novo Nordisk sells semaglutide as Ozempic (diabetes) and Wegovy (weight management). The pharmaceutical rationale is straightforward: separate indications allow separate pricing, marketing, and payer negotiations. For patients, it means the drug you receive depends partly on which diagnosis your prescriber documents.

Tirzepatide works as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [3]. This dual mechanism distinguishes it from single-target GLP-1 receptor agonists like semaglutide and liraglutide. The GIP component appears to amplify insulin secretion and may contribute to the larger A1C and weight reductions seen in head-to-head trials [4].

The Evidence for Tirzepatide in Type 2 Diabetes

Tirzepatide's glycemic efficacy is well-established through the SURPASS clinical trial program, a series of phase 3 studies enrolling over 20,000 participants with type 2 diabetes. These trials tested tirzepatide under the Mounjaro label, but the pharmacology is identical to Zepbound.

In SURPASS-1 (N=478), tirzepatide monotherapy reduced A1C by −1.87% at the 10 mg dose and −2.07% at the 15 mg dose over 40 weeks, compared to +0.04% with placebo [5]. More than 80% of patients on the 10 mg and 15 mg doses achieved an A1C below 7%.

SURPASS-2 (N=1,879) compared tirzepatide directly against semaglutide 1 mg. The results were decisive. Tirzepatide 15 mg reduced A1C by −2.46% versus −1.86% for semaglutide 1 mg [6]. Weight loss was also greater: −12.4 kg with tirzepatide 15 mg versus −6.2 kg with semaglutide. The American Diabetes Association (ADA) Standards of Care now include tirzepatide among preferred second-line agents for patients with type 2 diabetes who need both glycemic control and weight reduction [7].

SURPASS-3 (N=1,437) showed tirzepatide outperforming titrated insulin degludec over 52 weeks, with all three tirzepatide doses achieving greater A1C reductions and weight loss rather than weight gain [8]. SURPASS-4 (N=2,002) demonstrated cardiovascular safety in patients with established atherosclerotic cardiovascular disease, with tirzepatide showing superiority over insulin glargine for glycemic control [9].

Dr. Juan Pablo Frias, principal investigator for SURPASS-2, stated: "The A1C reductions observed with tirzepatide exceeded what we have seen with any other injectable glucose-lowering therapy in a controlled trial setting" [6].

Why Would Someone Use Zepbound Instead of Mounjaro?

This is the practical question. If Mounjaro exists for diabetes, why would a clinician prescribe Zepbound off-label for the same condition? Several real-world factors drive this pattern.

Supply shortages have intermittently affected both brands since their launch. During periods when Mounjaro pens are backordered at specific dose strengths, Zepbound at the same dose may remain available, or vice versa. Prescribers sometimes switch brands simply to keep patients on therapy without interruption.

Pricing differences can also play a role. Eli Lilly's direct-to-consumer savings programs for Zepbound and Mounjaro have different eligibility criteria. Some patients without commercial insurance coverage for Mounjaro have found Zepbound's savings card or LillyDirect pricing more accessible, though this varies by month and by plan.

A third scenario involves patients who carry both obesity and type 2 diabetes diagnoses. If a payer covers Zepbound for weight management but denies Mounjaro for diabetes (or vice versa), the prescriber may choose whichever brand the patient can actually obtain and afford.

None of these scenarios change the drug itself. A 10 mg Zepbound pen delivers exactly the same 10 mg of tirzepatide as a 10 mg Mounjaro pen [1][2].

Risks and Tradeoffs of Off-Label Prescribing

Off-label prescribing is legal and common in U.S. medicine. Roughly one in five outpatient prescriptions in the United States is written for an off-label indication, according to a study published in the Archives of Internal Medicine [10]. Physicians have broad discretion to prescribe FDA-approved medications for uses not specified on the label, provided they exercise sound clinical judgment.

The risks of using Zepbound off-label for diabetes are not pharmacological. They are logistical and regulatory.

Insurance and prior authorization. When Zepbound is prescribed with a type 2 diabetes diagnosis code (ICD-10 E11.x), payers may reject the claim because the drug's approved indication is obesity, not diabetes. This can result in full out-of-pocket cost to the patient, which may exceed $1,000 per month without a savings program. The ADA has noted that insurance barriers to GLP-1 receptor agonists remain a significant obstacle to optimal diabetes care [7].

Dose titration differences. The Zepbound prescribing information includes dose titration guidance developed from obesity trials (SURMOUNT program), while the Mounjaro label reflects titration data from diabetes trials (SURPASS program) [1][2]. The starting dose for both is 2.5 mg weekly for four weeks, then 5 mg weekly. Dose escalation schedules are similar but not identical in the labeling. A clinician prescribing Zepbound for diabetes should follow the diabetes-specific titration evidence from SURPASS, not the SURMOUNT titration schedule.

Safety monitoring gaps. The Mounjaro label includes diabetes-specific safety language about hypoglycemia risk when combined with insulin or sulfonylureas, dosing adjustments for renal impairment, and monitoring recommendations for diabetic retinopathy [2]. The Zepbound label does not emphasize these diabetes-specific warnings. A prescriber using Zepbound off-label must independently apply the relevant safety guidance from the Mounjaro label and ADA Standards of Care.

Medical-legal considerations. Off-label prescribing is protected when supported by evidence. Tirzepatide's diabetes evidence base is strong (five phase 3 trials, FDA approval under the Mounjaro brand). This is not a speculative off-label use. A physician prescribing Zepbound for type 2 diabetes can point to the identical molecule's full regulatory dossier, which significantly reduces liability exposure compared to off-label uses with weaker evidence.

Gastrointestinal Side Effects and Tolerability

The side effect profile of tirzepatide is consistent regardless of brand name. In the SURPASS trials, the most commonly reported adverse events were gastrointestinal: nausea (12−24%), diarrhea (13−17%), and decreased appetite (5−11%) [5][6]. In the SURMOUNT-1 obesity trial (N=2,539), nausea rates were somewhat higher, reaching 24−33% across tirzepatide dose groups, likely because obesity trial participants were not accustomed to incretin-based therapies [11].

Most GI symptoms peak during dose escalation and diminish within 4 to 8 weeks. Slow dose titration reduces severity. The 2.5 mg starting dose exists specifically to improve tolerability during initiation.

Serious but rare adverse events include pancreatitis (reported in <0.2% of trial participants), gallbladder-related events, and severe hypoglycemia when tirzepatide is combined with insulin or sulfonylureas [2]. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, based on preclinical thyroid C-cell tumor findings in rodents [1][2].

Dr. Ania Jastreboff, associate professor of medicine at Yale School of Medicine and principal investigator for SURMOUNT-1, has observed: "The benefit-risk profile of tirzepatide is favorable for both obesity and type 2 diabetes, but clinicians must individualize dose escalation based on tolerability, particularly in patients taking concurrent glucose-lowering medications" [11].

How Tirzepatide Compares to Other Diabetes Medications

Tirzepatide's dual GIP/GLP-1 mechanism produces larger A1C reductions than any currently available GLP-1 receptor agonist. The SURPASS-2 head-to-head trial against semaglutide 1 mg showed statistically significant superiority across all three tirzepatide doses [6].

Against insulin, tirzepatide performs even more distinctly. SURPASS-3 showed that tirzepatide 15 mg reduced A1C by −2.37% versus −1.34% for insulin degludec over 52 weeks. Weight divergence was striking: patients on tirzepatide lost an average of 12.9 kg while those on insulin gained 2.3 kg [8]. For patients with type 2 diabetes and concurrent obesity, this combination of glycemic and weight benefits is difficult to match with any other single agent.

The ADA 2024 Standards of Care position tirzepatide (as Mounjaro) alongside semaglutide as a preferred option for patients who need A1C reduction and weight loss, particularly when BMI is 27 or higher [7]. Metformin remains the first-line pharmacotherapy for most patients with type 2 diabetes, with GLP-1 receptor agonists or dual GIP/GLP-1 agonists recommended as add-on therapy when glycemic targets are not met.

SGLT2 inhibitors (empagliflozin, dapagliflozin) offer complementary benefits including cardiovascular and renal protection, but produce more modest A1C reductions (−0.5% to −0.8%) and weight loss (2−3 kg) compared to tirzepatide [12].

What the FDA Label Actually Says

The Zepbound prescribing information explicitly states: "Zepbound is not indicated for the treatment of type 2 diabetes mellitus" [1]. This is a regulatory distinction, not a pharmacological one. The FDA requires separate approval processes for each indication, and Eli Lilly chose to pursue the obesity indication under the Zepbound brand rather than expanding Mounjaro's label.

The Mounjaro prescribing information states it is indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" [2]. Both labels carry identical black box warnings about thyroid C-cell tumors.

Patients should understand that "not indicated for diabetes" on the Zepbound label does not mean "ineffective for diabetes" or "dangerous for diabetes." It means Eli Lilly did not submit the Zepbound brand for diabetes approval. The molecule itself has one of the strongest evidence bases for glycemic control of any diabetes medication approved in the last decade.

Who Should Consider This Option (and Who Should Not)

A patient with type 2 diabetes who can obtain Mounjaro through insurance or a savings program should use Mounjaro. The clinical evidence, label language, and payer alignment all favor the diabetes-indicated brand. This is the straightforward recommendation.

Off-label Zepbound for diabetes becomes a reasonable consideration when Mounjaro is unavailable due to supply constraints, when insurance covers Zepbound but not Mounjaro (typically in patients with both obesity and diabetes), or when cost through LillyDirect or a pharmacy benefit makes one brand significantly more affordable.

Patients who should not use tirzepatide in any form include those with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a history of serious hypersensitivity to tirzepatide [1][2]. Tirzepatide has not been studied in patients with type 1 diabetes and should not be used in that population. Patients with severe gastroparesis may not tolerate the GI effects.

Any patient using Zepbound off-label for diabetes should have A1C monitored every 3 months, receive diabetes-specific counseling about hypoglycemia signs (especially if taking sulfonylureas or insulin concurrently), and have their prescriber document the clinical rationale for the off-label choice.

The Cost Question

Without insurance or savings programs, both Zepbound and Mounjaro carry list prices exceeding $1,000 per month. Eli Lilly's LillyDirect program has offered tirzepatide at reduced cash-pay prices, though these prices and eligibility criteria change frequently [13].

For patients with commercial insurance, coverage depends entirely on the plan formulary and the diagnosis code. A patient with a primary diagnosis of obesity (E66.01) is more likely to receive Zepbound coverage. A patient with a primary diagnosis of type 2 diabetes (E11.65) is more likely to receive Mounjaro coverage. Patients carrying both diagnoses may need prior authorization appeals regardless of brand.

Medicare Part D generally does not cover anti-obesity medications, which means Zepbound is excluded for Medicare beneficiaries even if they also have diabetes. Mounjaro may be covered under Part D for the diabetes indication, though formulary placement and step therapy requirements vary by plan [14].

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, fully effective as of 2025, may reduce the financial burden for Medicare patients who can access Mounjaro on formulary [14].